Corrigendum: The Significance of Transarterial Chemo(embolization) Combined With Tyrosine Kinase Inhibitors and Immune Check Point Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review

• Qiao Ke,
• Qiao Ke,
• Fuli Xin,
• Fuli Xin,
• Huipeng Fang,
• Yongyi Zeng,
• Lei Wang,
• Lei Wang,
• Jingfeng Liu,
• Jingfeng Liu

Affiliations

Qiao Ke

Department of Hepatopancreatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China

Qiao Ke

College of Clinical Medicine for Oncology, Fujian Medical University, Fuzhou, Fujian, China

Fuli Xin

Department of Hepatopancreatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China

Fuli Xin

College of Clinical Medicine for Oncology, Fujian Medical University, Fuzhou, Fujian, China

Huipeng Fang

College of Clinical Medicine for Oncology, Fujian Medical University, Fuzhou, Fujian, China

Yongyi Zeng

Department of Hepatopancreatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China

Lei Wang

College of Clinical Medicine for Oncology, Fujian Medical University, Fuzhou, Fujian, China

Lei Wang

Department of Radiation Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian, China

Jingfeng Liu

Department of Hepatopancreatobiliary Surgery, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian, China

Jingfeng Liu

The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China